By Jahaira Lara
News
The rector of the UAQ recalled that work is being done to conclude the preclinical stage and advance to clinical phase I and II, after the redesign of the vaccine
On June 15, the group of researchers from the Autonomous University of Querétaro (UAQ) who are developing the QUIVAX 17.4 vaccine project will present the results of the work carried out this first semester of 2022, reported the rector, Teresa García Gasca.
In this sense, the academic specified that currently the work is focused on concluding the preclinical stage after the redesign of the vaccine, in order to give way to phase I and II of the tests in humans; while phase three, she assured, is outside the budget, so everything will depend on the political will and management that is achieved to move forward.
“We don’t know when we could be ready, our scope right now is to finish the preclinical stage and start the clinical stages in humans, which are the minor ones, phase I and II, but phase three is out of our budget reach. Arriving at phase two with our results, we have to do budget management to continue ”.
García Gasca pointed out that the World Health Organization is expected to declare the end of the pandemic before the end of the year, although he recalled that cases will continue to be registered seasonally, particularly in winter.
Therefore, he emphasized the importance of promoting the development of second-generation vaccines that show better results to deal with the virus and its variants, to which QUIVAX 17.4 is expected to belong.
The foregoing, by highlighting that the results shown by some emergency vaccines with which the population is immunized are less and less effective, which shows the need for vaccines that show better results and that only require one dose per year.
–
